Compare MGTX & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGTX | EVV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2003 |
| Metric | MGTX | EVV |
|---|---|---|
| Price | $13.84 | $9.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $24.57 | N/A |
| AVG Volume (30 Days) | ★ 588.5K | 439.7K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $81,391,000.00 | N/A |
| Revenue This Year | $141.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $6.62 | $8.97 |
| 52 Week High | $15.35 | $10.41 |
| Indicator | MGTX | EVV |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 45.03 |
| Support Level | $7.04 | $9.01 |
| Resistance Level | $15.35 | $9.32 |
| Average True Range (ATR) | 0.76 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.08 | 32.58 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.